Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Head & Neck 2Gynecologic 2Genitourinary 2Gastrointestinal 2Breast 2Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 4Advanced Solid Tumors 4Squamous Cell Carcinoma of Head and Neck 3Carcinoma, Renal Cell 3Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Stomach Neoplasms 2Ovarian Neoplasms 2Melanoma 2Esophageal Neoplasms 2Triple Negative Breast Neoplasms 1Solid Tumors 1Solid Tumor, Unspecified, Adult 1Solid Tumor 1Pharyngeal Neoplasms 1Pancreatic Neoplasms 1Oropharyngeal Neoplasms 1Neoplasms 1Multiple Myeloma 1Mouth Neoplasms 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Laryngeal Neoplasms 1Kidney Neoplasms 1Hypopharyngeal Neoplasms 1Head and Neck Neoplasms 1Erythrocytosis, Familial, 4 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Merkel Cell 1

Interventions

pembrolizumab 26Gemcitabine 20Cisplatin 12Nivolumab 11Carboplatin 8Paclitaxel 7Docetaxel 7atezolizumab 6durvalumab 5Radiotherapy 5fludarabine 4enfortumab vedotin 4Ipilimumab 4Cyclophosphamide 4Vorinostat 3Magnetic Resonance Spectroscopy 3Fluorouracil 3Filgrastim 3Doxorubicin 3zimberelimab 2vocimagene amiretrorepvec 2tremelimumab 2romidepsin 2poly ICLC 2infigratinib 2erdafitinib 2cc-486 2belinostat 2avelumab 2amminedichloro(2-methylpyridine)platinum(II) 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Urinary Bladder Neoplasms × zimberelimab × Clear all
NCT05891171 2026-03-31

ARC-25

Arcus Biosciences, Inc.

Phase 1 Active not recruiting
40 enrolled
BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

NCT03629756 2024-05-24

A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies

Arcus Biosciences, Inc.

Phase 1 Completed
48 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Ovarian Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡